Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

Frederikus A. Klok1,2 Walter Ageno3 Stefano Barco1 Harald Binder4,5 Benjamin Brenner6 Daniel Duerschmied7 Klaus Empen8 Pompilio Faggiano9 Joachim H. Ficker10 Nazzareno Galiè11 Alexandre Ghysen12 Matthias Held13 Nadine Heydenreich1 Menno V. Huisman2 David Jiménez14 Matija Kozak15 Irene M. Lang16 Mareike Lankeit1,17 Thomas Münzel18 Antoniu Petris19 Piotr Pruszczyk20 Kurt Quitzau1 Sebastian Schellong21 Kai-Helge Schmidt1,18 Branislav S. Stefanovic22 Franck Verschuren23 Anamaria Wolf-Puetz24 Guy Meyer25,26,27 Stavros V. Konstantinides1,28 for the PEITHO-2 Investigators

1 Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany
2 Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
3 Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
4 Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Johannes Gutenberg University, Mainz, Germany
5 Institute for Medical Biometry and Statistics, University of Freiburg, Freiburg, Germany
6 Department of Hematology and Bone Marrow Transplantation, Ruth and Bruce Rappaport Faculty of Medicine, Rambam Health Care Campus, Technion, Haifa, Israel
7 Department of Cardiology and Angiology I, Faculty of Medicine, University of Freiburg, Freiburg, Germany
8 Department of Cardiology, University Hospital, Greifswald, Germany
9 Cardiology Unit, Spedali Civili, Brescia, Italy
10 Department of Respiratory Medicine, Allergology and Sleep Medicine, General Hospital Nuenberg, Paracelsus Medical University, Nuenberg, Germany
11 Department of Investigational, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
12 Emergency Care, Department of Medicine, University Hospital Centre, Ljubljana, Slovenia
13 Medical Mission Hospital, Department of Internal Medicine, Center for Pulmonary Hypertension and Pulmonary Vascular Disease, Academic Teaching Hospital, Julius-Maximilian University of Wuerzburg, Wuerzburg, Germany
14 Department of Respiratory Diseases, Ramon y Cajal Institute for Health Research, Madrid, Spain
15 Department of Vascular Diseases, University Medical Center, Ljubljana, Slovenia
16 Department of Cardiology, Medical University of Vienna, Vienna, Austria
17 Division of Cardiology, Medical Department, Charité Campus Virchow-Klinikum, Berlin, Germany
18 Department of Cardiology University Medical Center, Mainz, Germany
19 Cardiology Clinic, St. Spiridon Clinical Emergency Hospital, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania
20 Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland
21 Municipal Hospital of Dresden-Friedrichstadt, Dresden, Germany
22 Coronary Care Unit, Cardiology Clinic, Emergency Center, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
23 Emergency Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
24 Department of Cardiology, Augusta-Krankenhaus, Duesseldorf, Germany
25 Pulmonology and Intensive Care Service, Assistance Publique Hôpitaux de Paris, Georges Pompidou European Hospital, Paris, France
26 Paris Descartes University, Paris, France
27 INSERM UMR S 970, Paris, INNOVTE, France
28 Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece

Address for correspondence Stavros V. Konstantinides, MD, PhD, Center for Thrombosis and Hemostasis, University Medical Center Mainz, Langenbeckstrasse 1, Building 403, 55131 Mainz, Germany (e-mail: stavros.konstantinides@unimedizin-mainz.de).

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Abstract

Patients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-vitamin K-dependent direct oral anticoagulants (NOACs) have been approved for the treatment of venous thromboembolism, their safety and efficacy as well as the optimal anticoagulation regimen using these drugs have not been systematically investigated in intermediate-risk PE. Moreover, it remains unknown how many patients with intermediate-high-risk and intermediate-low-risk PE were included in most of the phase III NOAC trials. The ongoing Pulmonary Embolism International Thrombolysis 2 (PEITHO-2) study is a prospective, multicentre, multinational, single-arm trial investigating whether treatment of acute intermediate-risk PE with parenteral heparin anticoagulation over the first 72 hours, followed by the direct oral thrombin inhibitor dabigatran over 6 months, is effective and safe. The primary efficacy outcome is recurrent symptomatic venous thromboembolism or death related to PE within the first 6 months. The primary safety outcome is major bleeding as defined by the International Society on Thrombosis and Haemostasis. Secondary outcomes include all-cause mortality, the overall duration of hospital stay (index event and repeated hospitalizations) and the temporal pattern of recovery of right ventricular function over the 6-month follow-up period. By applying and evaluating a contemporary risk-tailored treatment strategy for acute PE, PEITHO-2 will implement the recommendations of current guidelines and contribute to their further evolution.

Keywords
- dabigatran
- pulmonary embolism
- intermediate risk
- venous thromboembolism recurrence
- right ventricular function
- major bleeding

Background and Rationale

In patients with acute pulmonary embolism (PE), the risk of early death or haemodynamic collapse ranges from less than 1 to over 50%, depending on the severity of the acute episode as well as the cardiopulmonary reserves and comorbidity of the patient. Current European clinical practice guidelines place particular emphasis on early risk stratification to determine the optimal risk-adjusted treatment strategy. Patients with haemodynamic compromise or frank cardiogenic shock at presentation have at least 20% risk of early adverse events and should receive immediate reperfusion therapy, while those with low-risk PE, as defined in the 2014 Guidelines of the European Society of Cardiology (ESC), and no other indication for hospitalization should be considered for early discharge and home treatment. The remaining patients with acute PE are classified into the intermediate-risk category and depending on the method and the cut-off values used for definition, they may account for up to 60% of all PE patients and have up to 7.7% risk of early mortality.

The prognostic impact and therapeutic implications of intermediate-risk PE, and particularly the ‘upper zone’ of severity within this category, were highlighted by the results of the Pulmonary Embolism International Thrombolysis (PEITHO) trial. In the placebo (heparin-only) arm of PEITHO, the upper limit of the 95% confidence interval (CI) for the risk of haemodynamic decompensation was as high as 8% (mean 5.6%) in normotensive patients who presented both with right ventricular dysfunction on echocardiography or computed tomographic pulmonary angiography (CTPA), and with evidence of myocardial injury indicated by elevated cardiac troponin levels.

Historically, the standard therapeutic regimen for patients with acute PE has consisted of parenteral anticoagulation (intravenous unfractionated heparin, or subcutaneous low-molecular-weight heparin [LMWH] or fondaparinux) with overlapping administration of a vitamin K antagonist (VKA) until reaching a therapeutic range of the international normalized ratio (INR). More recently, four non-vitamin K-dependent direct oral anticoagulants (NOACs), that is, one direct thrombin inhibitor (dabigatran) and three factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) were demonstrated to be non-inferior and at least as safe as traditional treatment with LMWH and VKA, and subsequently approved for the treatment and secondary prevention of venous thromboembolism (VTE). These drugs, which do not require laboratory monitoring, were developed to overcome the limitations and risks that characterize the initial overlap of parenteral and oral anticoagulants and the subsequent chronic treatment with VKAs, notably the bleeding or thrombotic complications caused by unstable INR values. In the large phase III trials in patients with acute PE and/or deep vein thrombosis (DVT), NOAC treatment was associated with a significantly lower risk of major (relative risk [RR]: 0.60; 95% CI: 0.41–0.88) and fatal (RR: 0.36; 95% CI: 0.15–0.87) haemorrhage compared with VKAs, while having comparable efficacy (RR: 0.88; 95% CI: 0.74–1.05). Importantly, however, the safety and efficacy of NOAC in patients with intermediate-risk PE have not been systematically addressed in a dedicated trial thus far, and it is largely unknown what the overall number of patients with
acute intermediate-risk PE was in all but one of the phase III studies mentioned earlier.\textsuperscript{11–14}

The Hokusai-VTE phase III trial reported data for the subgroup of patients with acute PE and right ventricular (RV) dysfunction, defined as right-to-left ventricular (RV/LV) diameter ratio >0.9 on CT angiography, and for patients with N-terminal pro-brain natriuretic peptide (NT-proBNP) levels greater than 500 pg/mL.\textsuperscript{12,13} Recurrent VTE occurred in 14 of 465 patients with elevated NT-proBNP treated with LMWH followed by edoxaban and in 30 of 507 of their counterpart in the LMWH-warfarin group for a hazard ratio of 0.50 (95% CI: 0.26–0.94).\textsuperscript{15} Similar differences were observed in the subgroup of patients with both an elevated NT-proBNP level and a right-to-left ventricular ratio >0.9 on CTPA (hazard ratio: 0.44 [95% CI: 0.14–1.36]). When viewed together with the substantial risk of early decompensation and the possible need for rescue thrombolysis (or, alternatively, interventional or surgical therapy) in the intermediate-risk category, these results generate the hypothesis that an initial parenteral anticoagulation with subcutaneous LMWH, followed by an NOAC may be the safest approach for this patient group. In this regard, however, the minimum period after which treatment may be safely switched to oral anticoagulation remains to be defined.\textsuperscript{16} It is thus necessary to show whether patients may safely switch from parenteral heparin treatment to an NOAC already after the first 72 hours, that is, earlier than in the regimens tested in previous trials, and whether there is a subgroup of intermediate-risk patients that might need a more conservative approach with a longer heparin period before switching to an NOAC.\textsuperscript{11,12,17} Finally, a trial focusing on intermediate-risk PE should provide insights, using prospectively defined follow-up intervals and standardized outcome parameters, into the rate of recovery of RV function under anticoagulation for acute PE.

**Study Overview**

**Study Design and Objectives**

PEITHO-2 is a prospective, multicentre, multinational, single-arm management trial (NCT02596555, EudraCT 2015–001830–12). The main characteristics of the trial design are summarized in Table 1 against the background of recent trials using a heparin lead-in phase. PEITHO-2 is an investigator-initiated trial with an academic sponsor, the University Medical Center Mainz. The primary objective is to determine whether treatment of acute intermediate-risk PE with parenteral anticoagulation for 72 hours (rather than 5 days or longer currently required before the switch to dabigatran or edoxaban), followed by dabigatran over 6 months, is effective and safe. The secondary objectives are to assess the safety of the studied treatment regimen as well as the recovery of RV function assessed by serial echocardiograms, and the importance of this recovery for the 6-month prognosis of patients with acute intermediate-risk PE.

**Table 1** Overview of trials on non-vitamin K–dependent direct oral anticoagulants with a heparin lead-in phase

<table>
<thead>
<tr>
<th></th>
<th>RE-COVER\textsuperscript{11}</th>
<th>HOKUSAI-VTE\textsuperscript{12}</th>
<th>PEITHO-2 (present study)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Design</strong></td>
<td>Double-blind, double-dummy, non-inferiority phase III study</td>
<td>Double-blind, double-dummy, non-inferiority phase III study</td>
<td>Single-arm phase IV management study</td>
</tr>
<tr>
<td><strong>Treatment and dosage</strong></td>
<td>LMWH for minimum of 10 d followed by either dabigatran etexilate 150 mg bid or INR-adjusted warfarin</td>
<td>LMWH for a minimum of 7 d followed by either edoxaban 60 mg od or INR-adjusted warfarin</td>
<td>LMWH for 72 h, followed by dabigatran etexilate 150 mg bid*</td>
</tr>
<tr>
<td><strong>Duration (primary endpoint)</strong></td>
<td>6 mo</td>
<td>3–12 mo</td>
<td>6 mo</td>
</tr>
<tr>
<td><strong>Patients enrolled in the original trial</strong></td>
<td>5,128 patients with acute VTE</td>
<td>8,292 patients with acute VTE</td>
<td>700 patients with acute intermediate-risk PE</td>
</tr>
<tr>
<td><strong>Number of patients with PE in the trial population</strong></td>
<td>1,602 patients with acute PE</td>
<td>972 patients with acute PE and NT-proBNP ≥500 pg/mL</td>
<td>All study patients have acute intermediate-risk PE</td>
</tr>
<tr>
<td><strong>Primary efficacy outcome</strong></td>
<td>Recurrent VTE or death related to PE</td>
<td>Recurrent VTE or death related to PE</td>
<td>Recurrent VTE or death related to PE</td>
</tr>
<tr>
<td><strong>Efficacy outcome: results (PE patients only)</strong></td>
<td>2.9% (dabigatran) versus 3.1% (warfarin; HR: 0.93; 95% CI: 0.53–1.64)</td>
<td>3.0% (edoxaban) versus 5.9% (warfarin; HR: 0.50; 95% CI: 0.26–0.94)</td>
<td>Trial ongoing</td>
</tr>
<tr>
<td><strong>Primary safety outcome</strong></td>
<td>Major bleeding</td>
<td>Major bleeding</td>
<td>Major bleeding</td>
</tr>
<tr>
<td><strong>Safety outcome: results (all patients)</strong></td>
<td>1.2% (dabigatran) versus 1.7% (warfarin; HR: 0.69; 95% CI: 0.36–1.32)</td>
<td>1.4% (edoxaban) versus 1.6% (warfarin; HR: 0.84; 95% CI: 0.59–1.21)</td>
<td>Trial ongoing</td>
</tr>
</tbody>
</table>

Abbreviations: bid, twice daily; CI, confidence interval; HR, hazard ratio; LMWH, low-molecular-weight heparin; NT-proBNP, N-terminal pro-brain natriuretic peptide; od, once daily; PE, pulmonary embolism; PEITHO, Pulmonary Embolism International Thrombolysis; VTE, venous thromboembolism.

* A reduced dose of 110 mg twice daily is recommended for patients aged 80 years or older, and for those under concomitant treatment with verapamil, according to the European Summary of Product Characteristics (SmPC) for dabigatran.
Rationale for the Study Design

PEITHO-2 has prospectively defined and is evaluating a ‘dynamic’ strategy of risk-adjusted anticoagulation. This strategy encompasses (1) inclusion of patients with intermediate-risk PE, and further differentiation into intermediate-high and intermediate-low risk; (2) application of clinical and haemodynamic criteria for determining the earliest safe time point for the switch from parenteral to oral treatment and (3) analysis of the temporal pattern of RV recovery after acute intermediate-risk PE. To reach its objectives, PEITHO-2 was designed as a prospective management (cohort) trial without a control treatment arm. This was done for the following reasons.

Dabigatran is an already approved agent for the treatment of patients with acute PE, without excluding those with intermediate-risk PE. Although it is unknown how many of the patients included in the dabigatran phase III RECOVER trials belonged to the latter risk category, the members of the PEITHO-2 steering committee agreed that it would be inappropriate to repeat the randomized design of the RECOVER trials (dabigatran vs. VKA) within this focused study population. Instead, it is planned to analyse the data from PEITHO-2, upon completion, against the patient-level data from either treatment arm (dabigatran vs. warfarin) of the pooled RECOVER population. This will allow us to compare the efficacy and safety of dabigatran in the present trial with (1) the efficacy and safety of the same drug in the unselected RECOVER population.11 This will also serve to put the results of PEITHO-2 into perspective, while also fulfilling an important ethical requirement, namely keeping the number of patients and the complexity as well as the duration of the trial to the minimum required for adequately answering the study questions. This rationale was endorsed by the trial’s central ethics committee in Germany and by the ethics committees of the countries in which the trial is already recruiting.

Patient Population and Eligibility

The key inclusion and exclusion criteria are summarized in – Table 2. Patients with symptomatic acute, intermediate-risk PE, diagnosed by multidetector CT angiography,
ventilation/perfusion lung scan or selective invasive pulmonary angiography, with or without symptomatic DVT, who are haemodynamically stable at presentation, are eligible for enrolment in the study. The diagnosis of intermediate-risk PE is confirmed at each participating site, based on standardized diagnostic and risk stratification criteria and as recommended in current guidelines.\(^2\)

In contrast to Hokusai-VTE,\(^{12,15}\) PEITHO-2 uses the more practical and ‘intuitive’ \(^1.0\) threshold for defining an abnormally high RV/LV ratio, in agreement with other interventional trials\(^{10,18}\) and cohort studies\(^{19–21}\) in haemodynamically stable patients with acute PE. Furthermore, the threshold of 600 pg/mL is used in the inclusion criterion involving the biomarker NT-proBNP, as we have previously reported that this may be the most appropriate value for defining intermediate risk.\(^{22–24}\)

Current guidelines include the Pulmonary Embolism Severity Index (PESI) in the definition of intermediate-risk PE.\(^2\) However, despite the prognostic value of the PESI,\(^2\) it should be kept in mind that it was primarily designed as an epidemiological tool and not as a direct guide to PE management. Moreover, it has been reported that (severe) RV dysfunction may be present despite a simplified PESI of 0.\(^{26}\) If reproduced, this would be a relevant finding that could change future risk stratification algorithms. For these reasons, the present study does not use the simplified PESI as an inclusion criterion. Importantly, however, the index is prospectively calculated and documented in all patients, and it will thus be possible to determine if and how many study patients may exhibit a discordance between the clinical score and their imaging or biochemical parameters at presentation.

**Treatment Regimen**

In the RECOVER trials, the median duration of initial parenteral treatment with LMWH was 9 days.\(^{13,17}\) This was longer than the current average duration of hospitalization of patients with PE in Europe and North America, which generally does not exceed 4 to 6 days.\(^{27,28}\) Longer treatment periods with a parenteral anticoagulant before switching to an NOAC might delay the discharge of stable patients and thus increase treatment-related costs. Therefore, in this study, we are investigating the approach of an earlier switch from parenteral anticoagulants to dabigatran in clinically stabilized intermediate-risk PE patients.

The study flow is summarized in [Fig. 1](#). After enrolment, patients start or continue to receive LMWH at a therapeutic dosage for a period of 72 hours from the moment of PE diagnosis. If LMWH is not available, treatment with unfractionated heparin given by intravenous infusion is acceptable. The 72-hour duration of parenteral anticoagulation was chosen based on our previous PEITHO trial,\(^{10}\) in which the vast majority of early adverse outcomes (and thus cases of possible need for switch to rescue reperfusion therapy) in patients with intermediate-high-risk PE occurred within the first 3 days of randomization (unpublished data). Thereafter, and following clinical assessment of the patient’s condition, treatment is switched to oral dabigatran at the dosage of 150 mg twice daily. A reduced dose of 110 mg twice daily is recommended for patients aged 80 years or older, and for those under concomitant treatment with verapamil, according to the European Summary of Product Characteristics (SmPC) for dabigatran. The switch from LMWH to dabigatran is postponed by the investigator if (1) the patient is in shock, or haemodynamic collapse is considered imminent in view of deteriorating clinical parameters such as tachycardia, hypotension or dyspnoea and hypoxaemia; (2) the patient has received thrombolytic, surgical or catheter-directed treatment, or underwent cava filter implantation within the past 48 hours; (3) there is active bleeding or (4) the patient is, for

---

**Fig. 1** Overview of design of the PEITHO-2 (Pulmonary Embolism International Trial 2) study. PE, pulmonary embolism; I, inclusion; CE, clinical evaluation; T, time; LMWH, low-molecular-weight heparin.
any other reason, unable to receive oral anticoagulation. If at least one of these criteria is present, LMWH is continued and the eligibility for switching to dabigatran treatment is reassessed 48 hours later. Of note, the diagnostic workup and management of patients with early haemodynamic deterioration is based on local hospital protocols and the recommendations of current guidelines, and not dictated by the trial protocol.

Oral anticoagulation with dabigatran is continued for 6 months. An overview of the tests performed and the parameters collected upon enrolment and at the follow-up visits is provided in ▶ Table 3. After the end of the study period, the decision on whether to continue anticoagulation treatment, and which anticoagulant drug to administer, is left to the discretion of the physician(s) caring for the patient.

**Outcomes**

► Table 4 summarizes the outcomes of the PEITHO-2 trial. The primary efficacy outcome is the occurrence of recurrent symptomatic VTE or death related to PE within 6 months of therapy. Recurrent symptomatic DVT is confirmed by a new non-compressible venous segment on compression ultrasonography or by a new filling defect on CT venography. Recurrent symptomatic PE is diagnosed by a new filling defect on CT pulmonary angiography, or by a more proximal

### Table 3 Trial visit plan and data collection schedule

<table>
<thead>
<tr>
<th>Visit 1: enrolment (screening and baseline)</th>
<th>Visit 2: 72 (+12) h after PE diagnosis or 48 (+4) h later</th>
<th>Visit 3: discharge</th>
<th>Visit 4: FU 30 (+7) d after discharge</th>
<th>Visit 5: FU 180 (+14) d after discharge</th>
<th>Visit 6: FU 30 (+7) d after the end of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In hospital</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic data</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical examination</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>ECG</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sPESI</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VTE-BLEED</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTPA: RV/LV ratio</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Echocardiography</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood gas analysis</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Troponin I and/or t-test</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Further laboratory tests (NT-proBNP, renal and liver function)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Check inclusion and exclusion criteria</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obtain informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test (for women of childbearing age)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Check criteria for switch to oral therapy</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Documentation of</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Adverse eventsb</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>• Co-medications and therapies</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>• Rehospitalizationc</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>End of trial</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CTPA, computed tomographic pulmonary angiography; DVT, deep vein thrombosis; ECG, electrocardiogram; FU, follow-up; LV, left ventricular; NT-proBNP, N-terminal pro brain natriuretic peptide; PE, pulmonary embolism; RV, right ventricular; sPESI, simplified Pulmonary Embolism Severity Index.

*bParticularly death (and cause of death), haemodynamic deterioration, symptomatic recurrent VTE, major bleeding and clinically relevant non-major bleeding.

*cFor venous thromboembolism or bleeding.
obstruction of a previously occluded pulmonary artery, or by a new segmental mismatch on ventilation–perfusion lung scan. Death related to PE is defined as death following acute, objectively confirmed symptomatic recurrent PE or as sudden death not explained by another cause. The safety outcomes include major bleeding,29 non-major clinically relevant bleeding and occurrence of serious adverse events (Table 4). In addition, the recently developed and validated VTE-BLEED score will be prospectively evaluated with respect to its ability to predict bleeding events.30–32

The management of patients with severe haemorrhagic complications under anticoagulant treatment is based on local hospital protocols and the recommendations of current guidelines and consensus statements.33,34 It is not dictated by the protocol of the present trial.

All primary and secondary outcomes will be adjudicated by an independent committee, the members of which are mentioned in the Appendix A.

Sample Size Calculation and Statistical Analysis Plan

The expected incidence of the primary outcome of the present study is derived from data provided by Hokusai-VTE and PEITHO.10,12 Considering the definition of RV dysfunction in Hokusai-VTE, and the inclusion criteria of PEITHO (focusing on intermediate-high risk), we assumed that, in PEITHO-2, the incidence rate of the primary outcome in the total study population of ‘unselected’ intermediate-risk PE will be at least as high and possibly higher than that of the Hokusai study (3.3%), but it will not exceed the point estimate of that in the 6-month follow-up of the ‘intermediate-high-risk’ PEITHO trial (6.1%). Thus, assuming a 3.3% incidence of the primary outcome, we will test the null hypothesis (H0; probability [p] ≥ 0.061; 6.1%) against the alternative hypothesis (H1; p < 0.061) using a one-sided exact binomial test in a two-stage Pocock group sequential design. The significance level was chosen as α = 5%, leading to a nominal α = 0.003037 at the first stage. It is expected that 650 patients will provide a power of 90% for rejecting H0 (p ≥ 0.061) at the final stage if p is indeed 0.033. Taking into account a loss to follow-up of 7% maximum, a total number of 700 patients will have to be enrolled in PEITHO-2.

All analyses will be performed in the intention-to-treat population. We will consider our hypothesis that treatment with dabigatran preceded by at least 72 hours of parental anticoagulation is an effective treatment for patients with acute intermediate-risk PE as proven if the null hypothesis can be rejected, that is if 27 or less events are observed among 650 analysed patients.

A formal interim analysis is planned after 20% of the targeted patient population has been included and followed for 30 days. We will consider more than 11 events as an indication that it is no longer realistic to reject H0 in the further course of the trial, as the conditional power to reject the null hypothesis would then be below 50%. In this case, the Data Safety Monitoring Board may propose a protocol amendment that dictates that the switch from parenteral anticoagulants to dabigatran should be delayed to 5 ± 1 days in all patients.

Subgroups will be analysed with regard to the following outcomes: (1) primary outcome; (2) death or haemodynamic collapse or decompensation from any cause, PE-related death or haemodynamic collapse or decompensation, within the
first 30 days; (3) overall duration of hospital stay within 6 months; (4) death from any cause within 6 months and (5) all safety outcomes (Table 4). The prespecified variables and cut-offs for defining patient subgroups are the following: age (<75 vs. ≥75 years), sex, provoked versus unprovoked PE, patients with versus patients without cancer, presence versus absence of symptomatic confirmed DVT, patients with sPESI of 0 vs. 1 or higher at baseline, intermediate-low-risk versus intermediate-high-risk PE, baseline NT-proBNP (<600 vs. >600 pg/mL), shock to dabigatran after 72 hours versus switch after 5 days or later, echocardiographically assessed cardiac recovery versus no recovery and NT-proBNP levels (normalization vs. improvement vs. no improvement vs. deterioration). Finally, the rates of the primary efficacy outcome and major bleeding in the study population will be compared with those in either treatment arm (dabigatran or warfarin) of the pooled RECOVER population.11 In addition, the rates of the primary outcome and major bleeding in the predefined intermediate-high-risk subgroup of patients enrolled in the present trial will be compared with those in the placebo (heparin followed by VKA) arm of the PEITHO randomized controlled trial at 6-month follow-up.

Current Enrolment Status
As of August 2017, 26 sites have been initiated and a total a total of 77 patients have been enrolled at 15 active sites in five countries. Enrolment of the last patient is expected by the second quarter of 2019.

Implications of PEITHO-2
PEITHO-2 is the first clinical trial to apply a contemporary risk-tailored treatment strategy for acute PE, implementing and, possibly, further advancing the recommendations of current European guidelines.2 The first PEITHO study published in 2014 showed that patients at the ‘upper zone’ of the severity spectrum of intermediate-risk PE appeared to have an overall larger clinical benefit from a watchful waiting strategy. This consisted of initial anticoagulation, monitoring and rescue reperfusion treatment (only) in case of haemodynamic decompensation, rather than routine primary thrombolysis.11 PEITHO-2 continues to develop the risk-adjusted management strategy where PEITHO stopped. It investigates the strategy of parenteral anticoagulation followed by an early switch to oral treatment within the large intermediate-risk group of PE patients, and follows that group prospectively over a 6-month period (in PEITHO, follow-up beyond the first 30 days focused primarily on overall mortality).15 Comparison of the results of PEITHO-2 with the already available data from PEITHO will help put the efficacy and safety of the PEITHO-2 strategy into perspective. With the same objective, the results of PEITHO-2 will be compared with those from the phase III RECOVER trials with dabigatran, although possible differences in the clinical severity of PE, and the (expected) shorter duration of initial heparin anticoagulation in the present study, might pose some limitations in this regard.

If the hypothesis of PEITHO-2 is confirmed, patients with intermediate-risk PE will need only 72 hours of parenteral heparin treatment before switching to oral anticoagulation. This may offer the potential to safely reduce the duration of hospitalization for PE, with an impact on hospital-related complication rates, morbidity and costs. On the other hand, the PEITHO-2 study will also be able to determine which patients within the broad spectrum covered by intermediate-risk PE might need a more conservative approach with longer periods of parenteral heparin treatment. Finally, with its comprehensive follow-up strategy, the PEITHO-2 study will provide a deeper insight into RV recovery after acute PE, and its implications for the long-term prognosis of the patients.

Financial Support
PEITHO-2 is an independent, investigator-initiated trial. The study has an academic sponsor (University Medical Center Mainz, Germany) and is supported by public funding. In addition, the sponsor has obtained the study drug (dabigatran) and a grant from the market authorization holder of dabigatran, Boehringer Ingelheim. The authors are solely responsible for the design and conduct of the PEITHO-2 trial study, for all study analyses and for the drafting and editing of reports and publications and their final contents.

Authors’ Disclosures
Frederikus Klok reports research grants from Bayer, research grants from Bristol-Myers Squibb, research grants from Boehringer Ingelheim and non-financial research support from Daiichi Sankyo. Stefano Barco has received congress and travel payments from Daiichi Sankyo and Bayer HealthCare and financial support for the printing costs of his PhD thesis from Pfizer bv, CSL Behring bv, Sanquin Plasma Products, Boehringer Ingelheim bv, Aspen Netherlands and Bayer bv. Benjamin Brenner declares receiving honoraria for lectures and advisory board contributions from Pfizer, LEO Pharma, Sanofi and ROVI Laboratories. Matthias Held reports grants from Actelion, honoraria for lectures from Actelion, Bayer HealthCare, Berlin-Chemie, Boehringer Ingelheim, GSK, Novartis, Pfizer, honoraria for advisory board activities from Actelion, Bayer HealthCare, GSK, MSD and participation in clinical trials of Actelion, Bayer HealthCare, GSK, Pfizer, United Therapeutics, outside the submitted work. Daniel Duerschmied has received lecture honoraria from Bayer HealthCare and Pfizer and payment for travel accommodation/meeting expenses from Bayer HealthCare and Orion Pharma. Menno V. Huisman received research grants as well as fees for speaking and consulting from Boehringer Ingelheim, Bayer HealthCare, BMS-Pfizer, Daiichi Sankyo, MSD and Aspen. Guy Meyer reports travel support from Leo Pharma, BMS-Pfizer, Stago and Bayer HaelthCare and institutional grants from Leo Pharma, Bayer HaelthCare and BMS-Pfizer. Antoniu Petriș reports having received consultancy and lecture honoraria from Bayer HealthCare, Boehringer...
Ingelheim, Servier Pharma, AstraZeneca Pharma and BMS-Pfizer and payment for travel accommodation/meeting expenses from Bayer Healthcare and Boehringer Ingelheim. Franck Verschuren reports research support from Boehringer Ingelheim, Portola Pharmaceuticals, Daiichi Sankyo. Stavros Konstantinides reports having received consultancy and lecture honoraria from Bayer Healthcare, Boehringer Ingelheim, Actelion, Servier and BMS-Pfizer, payment for travel accommodation/meeting expenses from Bayer Healthcare and institutional grants from Boehringer Ingelheim, Bayer Healthcare, Daiichi Sankyo and Actelion.

Acknowledgements
The work of Frederikus Klok, Stefano Barco and Stavros Konstantinides was supported by the German Federal Ministry of Education and Research (BMBF 01EO1003 and 01EO1503). The authors are responsible for the contents of this publication. We are grateful to Sabrina Rump (Trial Unit of the Center for Thrombosis and Hemostasis, Mainz), Marco Villa and Raffaela Maucci (EXOM Group, Italy) and Philippe Gallula (APHP, France) for their contribution to the coordination of the PEITHO-2 study.

References

Appendix A

Study Committees and Investigators

Data safety monitoring board (DSMB): Adam Torbicki, Otwock, Poland (Chair); Marc Righini, Geneva, Switzerland (Member); Philippe Girard, Paris, France (Member); Walter Lehacher, Cologne, Germany (DSMB statistician).

Critical events adjudication committee: Claudia Dellas, Göttingen, Germany; Konstantinos Dimopoulos, London, United Kingdom; George Giannakoulas, Thessalonica, Greece.


Trial statistician: Harald Binder, Freiburg, Germany.

Operating institution of the Sponsor: Interdisciplinary centre for clinical trials (IZKS) Mainz.